Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study

Heart. 2009 Apr;95(7):570-6. doi: 10.1136/hrt.2008.152975. Epub 2008 Oct 24.

Abstract

Objective: To describe the contemporary features of coagulase-negative staphylococcal (CoNS) prosthetic valve endocarditis (PVE).

Design: Observational study of prospectively collected data from a multinational cohort of patients with infective endocarditis. Patients with CoNS PVE were compared to patients with Staphylococcus aureus and viridans streptococcal (VGS) PVE.

Setting: The International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) is a contemporary cohort of patients with infective endocarditis from 61 centres in 28 countries.

Patients: Adult patients in the ICE-PCS with definite PVE and no history of injecting drug use from June 2000 to August 2005 were included.

Interventions: None.

Main outcome measures: Heart failure, intracardiac abscess, death.

Results: CoNS caused 16% (n = 86) of 537 cases of definite non-injecting drug use-associated PVE. Nearly one-half (n = 33/69, 48%) of patients with CoNS PVE presented between 60 days and 365 days of valve implantation. The rate of intracardiac abscess was significantly higher in patients with CoNS PVE (38%) than in patients with either S aureus (23%, p = 0.03) or VGS (20%, p = 0.05) PVE. The rate of abscess was particularly high in early (50%) and intermediate (52%) CoNS PVE. In-hospital mortality was 24% for CoNS PVE, 36% for S aureus PVE (p = 0.09) and 9.1% for VGS PVE (p = 0.08). Meticillin resistance was present in 68% of CoNS strains.

Conclusions: Nearly one-half of CoNS PVE cases occur between 60 days and 365 days of prosthetic valve implantation. CoNS PVE is associated with a high rate of meticillin resistance and significant valvular complications.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bioprosthesis
  • Coagulase
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Cross Infection / mortality
  • Drug Resistance, Microbial
  • Endocarditis, Bacterial / drug therapy
  • Endocarditis, Bacterial / microbiology*
  • Endocarditis, Bacterial / mortality
  • Female
  • Heart Valve Prosthesis*
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications / drug therapy
  • Postoperative Complications / microbiology*
  • Postoperative Complications / mortality
  • Prospective Studies
  • Prosthesis-Related Infections / drug therapy
  • Prosthesis-Related Infections / microbiology*
  • Prosthesis-Related Infections / mortality
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / mortality
  • Staphylococcus aureus
  • Statistics, Nonparametric
  • Time Factors

Substances

  • Coagulase